Arcus Biosciences, Inc. SEC filings RCUS
Arcus Biosciences, Inc. has 609 filings in SEC EDGAR's recent list, going back to Dec 15, 2017. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| CT ORDER | Filing | Sep 28, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2022 | — |
| CORRESP | Letter to the SEC | Jun 3, 2022 | — |
| UPLOAD | Letter from the SEC | May 10, 2022 | — |
| EFFECT | Filing | Apr 25, 2019 | — |
| CORRESP | Letter to the SEC | Apr 23, 2019 | — |
| CT ORDER | Filing | Nov 16, 2018 | — |
| CT ORDER | Filing | Mar 15, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2018 | — |
| EFFECT | Filing | Mar 14, 2018 | — |
| CORRESP | Letter to the SEC | Mar 12, 2018 | — |
| CORRESP | Letter to the SEC | Mar 12, 2018 | — |
| CERT | Nyse cert- arcus biosciences, inc. | Mar 12, 2018 | — |
| 8-A12B | Form 8-a12b | Mar 9, 2018 | — |
| CORRESP | Letter to the SEC | Mar 5, 2018 | — |
| CORRESP | Letter to the SEC | Feb 20, 2018 | — |
| CORRESP | Letter to the SEC | Feb 16, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 15, 2018 | — |
| DRSLTR | Filing | Feb 5, 2018 | — |
| DRS/A | Filing | Feb 5, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2018 | — |
| DRSLTR | Filing | Jan 19, 2018 | — |
| DRS/A | Filing | Jan 19, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2018 | — |
| DRS | Filing | Dec 15, 2017 | — |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RCUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Hayward, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1724521
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.